Abstract
A novel virulent bacteriophage, φAbp2, infecting multidrug-resistant (MDR) Acinetobacter baumannii was isolated from the wastewater of a sewage management centre at Southwest Hospital, China. Transmission electron microscopy and phylogenetic analysis revealed that φAbp2 belongs to the subfamily Peduovirinae. A one-step growth curve demonstrated that φAbp2 had a latent period of 15 min, a lysis period of 35 min, and a burst size of 222 particles per infected host cell. Moreover, φAbp2 showed a relatively broad host range in local A. baumannii, and it also exhibited tolerance over a wider range of thermal and pH conditions. Genomic sequencing revealed that φAbp2 has a circular double-stranded DNA genome with no sequence similarity to our previously isolated φAbp1. Eighty-eight putative open reading frames (ORFs) encoding 41 proteins of known function and 47 of unknown function were identified, and the G/C content was 37.84%. φAbp2 is a new member of the subfamily Peduovirinae of the family Myoviridae. Its genome sequence is very similar to that of the A. baumannii phage LZ35.
Highlights
Acinetobacter baumannii is a growing threat that is responsible for numerous healthcare-associated infections, such as burn and wound infections [1]
ΦAbp2 targeting an MDR A. baumannii strain was screened from the sewage management centre at Southwest Hospital
We present the characterization and genomic annotation of φAbp2, a lytic phage from a clinical MDR A. baumannii isolate with strong lytic ability and a wider host range than those of our previously screened bacteriophages [14]
Summary
Acinetobacter baumannii is a growing threat that is responsible for numerous healthcare-associated infections, such as burn and wound infections [1]. It is among the leading causes of infections of the respiratory and urinary tracts, secondary meningitis, and sepsis [2]. Some strains of this widespread Gram-negative pathogen have been reported recently to be resistant to most known antibiotics, and there is an urgent need to find alternative treatments for these infections [3, 4].
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
